Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Crispr Therapeutics (CRSP) reported encouraging updated Phase I data for its in vivo liver editing candidate CTX310, showing up to 82% reduction ...